Skip to content
777 Sourcing.

Capability

autologous cell processing at patient bedside

Suppliers
1
States & provinces
1
Countries
1

1 autologous cell processing at patient bedside supplier across 1 states and provinces in 1 country. Profiles show capabilities, materials, certifications, and facility locations so you can compare shops and build a shortlist.

Suppliers

BIOCARDIA, INC.

SUNNYVALE, CA

BioCardia, Inc. is developing cellular and cell-derived therapeutics for the treatment of unmet cardiovascular and pulmonary diseases. Its lead program is the CardiAMP autologous mononuclear cell therapy for ischemic heart failure with reduced ejection fraction (HFrEF), manufactured at the patient's bedside using the proprietary CardiAMP cell processing system and delivered via a catheter-based minimally invasive approach. Its allogeneic mesenchymal stem cell platform is advanced as CardiALLO for heart failure and PulmALLO for acute respiratory distress

allogeneic mesenchymal stem cell manufacturingcell therapy developmentminimally invasive catheter-based targeted delivery

Compiled from public sources

Related capabilities

Other processes offered by the shops that list autologous cell processing at patient bedside.

Browse all capabilities